Schiffmann R - Search Results

1

Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.

Schiffmann R, Pastores GM, Lien YH, Castaneda V, Chang P, Martin R, Wijatyk A. Schiffmann R, et al. Orphanet J Rare Dis. 2014 Nov 26;9:169. doi: 10.1186/s13023-014-0169-6. Orphanet J Rare Dis. 2014. PMID: 25425121 Free PMC article. Clinical Trial.

2

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources.

Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO. Grabowski GA, et al. Among authors: schiffmann r. Ann Intern Med. 1995 Jan 1;122(1):33-9. doi: 10.7326/0003-4819-122-1-199501010-00005. Ann Intern Med. 1995. PMID: 7985893 Clinical Trial.

3

Enzyme replacement therapy in Fabry disease.

Brady RO, Murray GJ, Moore DF, Schiffmann R. Brady RO, et al. Among authors: schiffmann r. J Inherit Metab Dis. 2001;24 Suppl 2:18-24; discussion 11-2. doi: 10.1023/a:1012451320105. J Inherit Metab Dis. 2001. PMID: 11758675 Review.

4

Pediatric Fabry disease.

Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, Rosing DR, Robinson C, Schaefer E, Gal A, Dambrosia JM, Garman SC, Brady RO, Schiffmann R. Ries M, et al. Among authors: schiffmann r. Pediatrics. 2005 Mar;115(3):e344-55. doi: 10.1542/peds.2004-1678. Epub 2005 Feb 15. Pediatrics. 2005. PMID: 15713906

5

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.

Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Schiffmann R, et al. Nephrol Dial Transplant. 2006 Feb;21(2):345-54. doi: 10.1093/ndt/gfi152. Epub 2005 Oct 4. Nephrol Dial Transplant. 2006. PMID: 16204287 Clinical Trial.

6

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R. Ries M, et al. Among authors: schiffmann r. Pediatrics. 2006 Sep;118(3):924-32. doi: 10.1542/peds.2005-2895. Pediatrics. 2006. PMID: 16950982 Clinical Trial.

7

Cellular and tissue distribution of intravenously administered agalsidase alfa.

Murray GJ, Anver MR, Kennedy MA, Quirk JM, Schiffmann R. Murray GJ, et al. Among authors: schiffmann r. Mol Genet Metab. 2007 Mar;90(3):307-12. doi: 10.1016/j.ymgme.2006.11.008. Epub 2006 Dec 22. Mol Genet Metab. 2007. PMID: 17188539 Free PMC article.

8

Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents.

Ries M, Clarke JT, Whybra C, Mehta A, Loveday KS, Brady RO, Beck M, Schiffmann R. Ries M, et al. Among authors: schiffmann r. J Clin Pharmacol. 2007 Oct;47(10):1222-30. doi: 10.1177/0091270007305299. Epub 2007 Aug 13. J Clin Pharmacol. 2007. PMID: 17698592 Clinical Trial.

9

The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease.

Clarke JT, West ML, Bultas J, Schiffmann R. Clarke JT, et al. Among authors: schiffmann r. Genet Med. 2007 Aug;9(8):504-9. doi: 10.1097/GIM.0b013e318133fb1b. Genet Med. 2007. PMID: 17700388 Free article. Clinical Trial.

10

Fabry disease.

Schiffmann R. Schiffmann R. Pharmacol Ther. 2009 Apr;122(1):65-77. doi: 10.1016/j.pharmthera.2009.01.003. Epub 2009 Feb 8. Pharmacol Ther. 2009. PMID: 19318041 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

323 results

Search Page